Endo International PLC

Endo International — Q4 2021 Earnings Presentation

21 slides from Endo International's earnings presentation, Feb 28, 2022

  1. Slide 1: Q4 and FY 2021 Earnings Report

    Q4 and FY 2021 Earnings Report endo.com ©2022 Endo International plc or one of its affiliates. All rights reserved

  2. Slide 2: Forward Looking Statements; Non-GAAP Financial Measures

    Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “int

  3. Slide 3: Today's Agenda

    Today’s Agenda  Strategic Priorities  Business Performance  Pipeline Update  Financial Results & Guidance  Q&A 2 ©2022 Endo International plc or one of its affiliates. All rights reserved

  4. Slide 4: Endo: A Diversified Specialty Pharmaceutical Company

    Endo: A Diversified Specialty Pharmaceutical Company Our Vision Helping everyone we serve live their best life. Our Mission We develop and deliver life-enhancing products through focused execution. Our Strategic Priorities Expand & Reinvent How Be A Force Enhance Our We Work For Good Portfolio 3 ©20

  5. Slide 5: Q4 and FY 2021 Snapshot

    Q4 and FY 2021 Snapshot Revenues (U.S. $M) Q4 2021 Q4 2020 FY 2021 FY 2020 Branded Pharmaceuticals $228 $225 $ 894 $782 Sterile Injectables $319 $332 $1,266 $1,239 Generic Pharmaceuticals $218 $180 $741 $783 International Pharmaceuticals $ 24 $ 23 $93 $99 Total Revenues $789 $760 $2,993 $2,903 Adjus

  6. Slide 6: Q4 2021 Performance

    Q4 2021 Performance (Reported Revenues in $ millions) Branded Pharmaceuticals $225m $228m Y-o-Y Change $67m  Despite increasing COVID-19 driven $71m Branded Pharm. 2% pressures, XIAFLEX® revenue grew driven by Specialty Products 4% increased net price and improving patient $161m demand compared to

  7. Slide 7: Q4 2021 Performance

    Q4 2021 Performance (Reported Revenues in $ millions) Generic Pharmaceuticals Y-o-Y Change  Increase primarily due to 2021 product Generic launches, including varenicline tablets, only $218m Pharmaceuticals 21% $180m FDA approved generic of CHANTIX®, and lubiprostone capsules, first authorized gene

  8. Slide 8: Varenicline: Poised to Optimize Opportunity

    Varenicline: Poised to Optimize Opportunity Varenicline Molecule (TRx)  Currently, only FDA-approved generic 300,000 Chantix® Shortages on the market 250,000 Start 200,000 Endo Enters  Vertically integrated from API to final 150,000 finished product 100,000  Expanding capacity to meet demand 50,0

  9. Slide 9: XIAFLEX: Maximizing for Long Term Value

    XIAFLEX®: Maximizing for Long Term Value Current On-market Indications Peyronie’s Disease  Condition awareness campaign: specific request for XIAFLEX® honored 65-70% of the time by HCP  Opportunity to further “medicalize” the situation Dupuytren’s Contracture  New unbranded 2022 campaign featurin

  10. Slide 10: QWO: Focus on Creating Cornerstone Cellulite Treatment

    QWO®: Focus on Creating Cornerstone Cellulite Treatment 2021: Building the foundation Ongoing Studies & Data Generation >1,800 > 7.3B 224 CCH injected in grid pattern in non- obese subjects with mild to Final results expected in Q1’22 moderate cellulite of the Certified Offices Media Impressions thi

  11. Slide 11: Sterile Injectables and Generics Pipeline

    Sterile Injectables and Generics Pipeline Reflects Focus on More Durable and Differentiated Sterile Products Sterile Injectable Product Continuum Pending Filings – by Product Category 18% Generic Retail Less More differentiated differentiated Traditional Long Acting Drug/Device 18% Generic Specialty

  12. Slide 12: Vasostrict RTU bottles: Improved efficiency, reduced labor

    Launched Vasostrict® RTU bottles: Improved efficiency, reduced labor Multiple Steps: One Step: Draw, Dilute, Mix, Spike Spike  RTU product adoption can free up pharmacy and nursing to complete other tasks  Decreased risk for preparation or contamination errors  Enhanced medication safety for pati

  13. Slide 13: Q4 2021: Financial Results (Continuing Operations)

    Q4 2021: Financial Results (Continuing Operations*) US GAAP Non-GAAP (U.S. $, and Shares in millions) Q4 ’21 Q4 ’20 Q4 ’21 Q4 ’20 Total Revenues, net $789 $760 $789 $760 Gross Margin % 60.6% 51.4% 72.1% 66.4% Operating (Loss) Income $(419) $131 $367 $326 (Loss) Income $(557) $141 $200 $176 Effective

  14. Slide 14: Q1 2022 Financial Guidance (Continuing Operations)

    Q1 2022 Financial Guidance (Continuing Operations*) Measure Q1’2022 Total Revenues, net $595M – $635M Adjusted EBITDA $240M – $260M Adjusted Diluted Net Income per Share $0.35 – $0.45 The Company’s Q1’22 Financial Guidance is Based on the Following Assumptions: Measure Q1’2022 Adjusted Gross Margin

  15. Slide 15: Q1 2022 Segment Revenue Assumptions

    Q1 2022 Segment Revenue Assumptions Segment Q1’22 vs. Q1’21 % Revenue Change Branded Pharmaceuticals Mid to high single digit decline Sterile Injectables Mid 20’s to low 30’s decline Generic Pharmaceuticals In-line to low single digit decline International Pharmaceuticals Mid single digit decline To

  16. Slide 16: Cash Flow Prior to Debt Payments

    Cash Flow Prior to Debt Payments Q1 2022 Guidance Q1 2021 2021 2020 (Current) YTD US $M Actual Actual Low High Actual Adjusted EBITDA $1,481 $1,396 $240 $260 $365 Cash Interest ($541) ($535) ~($80) ($105) Changes in Net Working Capital $19 ($115) ~$0 $43 Cash Taxes, Net Refund (Payments) $48 $20 ~($

  17. Slide 17: Our Strategic Priorities

    Our Strategic Priorities Expand & Reinvent How Be A Force Enhance Our We Work For Good Portfolio We are investing to build We are embracing the We are committed to a more differentiated and future by accelerating the adoption of more durable portfolio that new ways of working to sustainable practice

  18. Slide 18: Q&A

    Q&A 17 ©2022 Endo International plc or one of its affiliates. All rights reserved

  19. Slide 19: Appendix

    Appendix 18 ©2022 Endo International plc or one of its affiliates. All rights reserved

  20. Slide 20: Cash Conversion Cycle

    Cash Conversion Cycle We use days sales outstanding (DSO), days inventory outstanding (DIO) and days payable outstanding (DPO), the sum of which is the cash conversion cycle, to evaluate our working capital performance. The following table summarizes the details of the financial metrics used to calc

  21. Slide 21: Thank you

    Thank you endo.com ©2022 Endo International plc or one of its affiliates. All rights reserved

Endo International — Q4 2021 Earnings Presentation on 6ix